“Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials” (2021) SKIN The Journal of Cutaneous Medicine, 5(1), p. s11. doi:10.25251/skin.5.supp.11.